Zacks Small Cap Issues Positive Estimate for Imunon Earnings

Imunon, Inc. (NASDAQ:IMNN) – Zacks Small Cap boosted their FY2024 EPS estimates for shares of Imunon in a note issued to investors on Monday, November 11th. Zacks Small Cap analyst D. Bautz now expects that the company will post earnings of ($1.74) per share for the year, up from their prior forecast of ($1.90). The consensus estimate for Imunon’s current full-year earnings is ($1.68) per share.

Imunon (NASDAQ:IMNN) last issued its earnings results on Wednesday, August 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.04.

Several other analysts also recently commented on IMNN. HC Wainwright cut their target price on Imunon from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday. EF Hutton Acquisition Co. I raised Imunon to a “strong-buy” rating in a research report on Monday, September 23rd.

Imunon Price Performance

Shares of IMNN opened at $0.75 on Wednesday. Imunon has a twelve month low of $0.48 and a twelve month high of $3.65. The company has a market capitalization of $44.92 million, a P/E ratio of -0.40 and a beta of 2.14. The firm has a 50 day moving average of $0.99 and a 200 day moving average of $1.18.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.